期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
The CXCR3alt-CXCL11 axis in bladder cancer: potential for prediction of neoadjuvant chemotherapy response
1
作者 Stephen Chenard drobert siemens Madhuri Koti 《Cellular & Molecular Immunology》 SCIE CAS CSCD 2021年第7期1631-1633,共3页
Muscle-invasive bladder cancer(MIBC)constitutes-25%of newly diagnosed bladder cancer cases.Patients with MIBC are optimally treated with platinum-based neoadjuvant chemotherapy(NAC)prior to radical cystectomy,which im... Muscle-invasive bladder cancer(MIBC)constitutes-25%of newly diagnosed bladder cancer cases.Patients with MIBC are optimally treated with platinum-based neoadjuvant chemotherapy(NAC)prior to radical cystectomy,which improves overall survival compared to surgery alone.While the goal of NAC is to downstage the primary tumor and afford early systemic treatment of micrometastasis,more than 60%of patients receiving NAC will not demonstrate significant local responses.Without accurate biomarkers predicting those that will benefit from NAC,a large cohort of patients will not only be exposed to the side effects of chemotherapy but also unnecessarily be subjected to delayed curative surgical intervention.This dilemma in the current management of patients with this aggressive disease highlights the importance of a recent discovery by Vollmer and colleagues,who reported that the intratumoral CXCR3alt-CXCL11 chemokine axis may be associated with the response to NAC in MIBC. 展开更多
关键词 CXCR3 BLADDER CHEMOTHERAPY
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部